Cell Phones and Brain Cancer -- Jury Still Out

Roxanne Nelson

Authors and Disclosures

October 14, 2009 — Cellular telephones have become an integral part of everyday life; they are now used by an estimated 4 billion people worldwide. But this is a relatively new technology, and there are lingering concerns about health risks, in particular a risk for brain cancer.

A new report suggests that that regular use of cell phones can result in a "significant" risk for brain tumors. But previous studies have been inconsistent. Even so, some European countries have taken precautionary measures, aimed specifically at children.


In the United States, a recent Senate hearing examining the safety of cell phones was inconclusive, saying that although more research is needed, it might be wise to begin taking precautionary measures right now. The National Cancer Institute also said that additional research is needed.

In this special feature, Medscape Oncology presents the views of experts from both sides of the case.

The new report, "Cellphones and Brain Tumors: 15 Reasons for Concern. Science, Spin and the Truth Behind Interphone," was released in August by the International Electromagnetic Field (EMF) Collaborative, a group that includes Powerwatch and the Radiation Research Trust in the United Kingdom, and the EMR Policy Institute, ElectromagneticHealth.org, and The Peoples Initiative Foundation in the United States.

More than 40 scientists and officials from 14 countries endorsed the report, which concluded that:
Studies that are independent of the telecom industry consistently show there is a "significant" risk for brain tumors from cell phone use.
The EMF exposure limits advocated by industry and used by governments are based on a false premise that a cell phone's electromagnetic radiation has no biological effects except for heating.
The danger of brain tumors from cell phone use is highest in children, and the younger a child is when he/she starts using a cell phone, the higher the risk.

"We have had zero reaction from the industry about the paper," Lloyd Morgan, a retired electronics engineer, an active member of several international science organizations, and the report's lead author, told Medscape Oncology. "What they're doing is a nonresponse response; they haven't challenged anything in it."

This report has intensified a controversy that has been brewing for nearly 2 decades and still remains largely unresolved. Approximately 30 epidemiologic studies have attempted to evaluate a possible association between cell phone use and the risk for brain and salivary gland tumors. There have also been a number of experimental studies involving cell cultures and animal models.

Results, however, have been inconclusive or even contradictory. But studies independent of industry funding have more consistently found higher risks for brain tumors when exposure was 10 or more years, explained Mr. Morgan, adding that "even some industry-funded studies show that there is a connection between cell phone use and the risk of brain tumors."

Interphone Results Flawed

The issue of cell phone safety was to have been settled once and for all by the huge 13-nation industry-funded Interphone study, which was begun nearly 10 years ago. Even though data collection was completed in 2004, the results have still not been published. The European Parliament has called the delay "deplorable," and has demanded an explanation for it. Although the combined results have not yet been released, 14 Interphone studies (11 single country and 3 multicountry studies) with partial results have been published.

"Results of Interphone have been delayed by about 4 years," said Elizabeth Barris, founder of the nonprofit People's Initiative Foundation and coauthor of the new report, in an interview. "It was supposed to be released this September. We wanted to make sure that our report was released before Interphone. We wanted to bring attention to the issue, including the fact that Interphone has been delayed for so long."

With only 4 exceptions, the industry-funded Interphone studies found no increased risk for brain tumors from cell phone use, explained Mr. Morgan. In contrast, a series of Swedish studies, led by Lennart Hardell, MD, PhD, from the Department of Oncology, Orebro Medical Center, in Sweden, which were independent of industry funding, reported numerous findings of significantly increased brain tumor risk from cell phone and cordless phone use.

An analysis of the results from the Interphone studies suggests that the use of a cell phone actually protects the user from a brain tumor, or that the studies had serious design flaws. "In any one study, you can see this incredibly skewing toward protection," said Mr. Morgan. "As you review these studies, you begin to get strong evidence of extremely improbable results."

In fact, Mr. Morgan and his coauthors identified 11 flaws in the Interphone studies: selection bias, insufficient latency time, definition of "regular" cell phone use, exclusion of young adults and children, no investigation of brain tumor risk from cell phones radiating higher power levels in rural areas, exclusion of exposure to other transmitting sources, exclusion of some brain tumor types, exclusion of tumors outside the cell phone radiation plume, exclusion of brain tumor cases because of death or illness, recall accuracy of cell phone use, and funding bias.

"Almost all flaws caused an underestimation of risk," he said, "and for exposure under 10 years, they found protection for cell phones."

The Cellular Telecommunications Industry Association (CTIA), the wireless association's industry trade group, has not specifically responded to the new report, according to Mr. Morgan. However, John Walls, vice president of public affairs at CTIA, told Medscape Oncology that "since we are not a scientific organization, with respect to the matter of health effects associated with wireless base stations and the use of wireless devices, CTIA and the wireless industry have always been guided by science and the views of impartial health organizations."

Peer-reviewed scientific evidence has overwhelmingly indicated that wireless devices do not pose a public health risk, Mr. Walls said. "In addition, there is no known mechanism for microwave energy within the limits established by the [Federal Communications Commission] to cause any adverse health effects," he said. "That is why the leading global heath organizations, such as the American Cancer Society, the National Cancer Institute, the World Health Organization, and the US Food and Drug Administration, all have concurred that wireless devices are not a public health risk."

Initial Red Flags

In the United States, the possible connection between tumors and cell phone use became highly publicized in 1993, when Florida resident David Reynard appeared on the popular television show Larry King Live and blamed cell phones for causing his wife's lethal brain tumor. Mr. Reynard filed a lawsuit against the manufacturer; he ultimately lost the case, but dozens of other lawsuits followed in its wake, along with numerous scientific studies that attempted to find or disprove a link. Most of the lawsuits have been dismissed, and thus far, none have gone to trial.

But the subject was picked up by the media, and scientists and experts argued publicly on opposing sides of the issue. Reports in the popular media prompted Congressional hearings on the safety of cell phone use, and during those sessions, it became clear that cell phones had not been tested for "safety prior to going into commerce," said George Carlo, PhD, MS, JD, during a 2008 radio interview with CFRO, a co-op radio station based in Vancouver, British Columbia. "Because the food and drug industry had not required that testing, Congress asked the industry to fill in those data gaps."

The industry invested $28.5 million and launched the first telecommunications industry-backed studies to investigate possible health risks stemming from cell phone use. Dr. Carlo, who is a Fellow of the American College of Epidemiology and has served on the faculty of several medical schools, headed the Wireless Technology Research program, which ran from 1993 to 1999. It was the largest program in the world to look at the potential dangers of cell phone use and electromagnetic radiation.

"In the middle of 1998, we began to have some of our long-term studies completed and it became clear that we were seeing things that no one expected," said Dr. Carlo. "We found that cell phone radiation caused leakage in the blood–brain barrier, it caused genetic damage in the form of disruption of normal DNA repair, and it caused more than a doubling of the risk of rare neuroepithelial tumors."

"After 6 years," he continued, "we found that cell radiation caused an increased risk of acoustic neuromas."

During the time these Wireless Technology Research studies were being carried out, the use of cell phones mushroomed. In 1993, there were 15 million cell phone users in North America; by 1999, there were more than 100 million.

"We went back to the industry and suggested that they issue warnings, but they promptly said no," Dr. Carlo said in the interview. "Those of us running the research program knew we had an ethical responsibility to go public with those findings, and we did go public, independent of the industry and independent of the government agencies that were overseeing the work."

In 2001, Dr. Carlo coauthored a book entitled Cell Phones. Invisible Hazards in the Wireless Age: An Insider's Alarming Discoveries, which discussed the findings.

Dr. Carlo felt that part of the reason for the refusal to issue warnings was that the telecommunications industry was not prepared for the results of the research. "I don't think they ever really expected to find that cell phones were dangerous, and when we presented our findings, they were ill prepared for them. They also didn't want to compromise their industry."

As for the lack of action on the part of government regulatory agencies, Dr. Carlo pointed out that agencies in the United States and Canada did not require any premarket testing of cell phones. "The only legal jurisdiction step that they had available in 1999 was to ban cell phones. And from a political point of view, banning cell phones would not be an easy thing to do, especially since our findings were the first ones of their type," he said.

These were "red flags of risk"; there weren't enough data at the time to actually prove that the risk was real, Dr. Carlo emphasized. "That is not the case now; there has been confirmatory evidence. But in 1999, regulatory agencies did not have the scientific evidence to be able to sustain the types of legal challenges that would have come from the industry had they tried to ban cell phones."

Trail of Research

Much of the more recent research on the safety of cell phones has not specifically found a health risk; however, researchers have pointed out the limitations of their studies and left the door open. Part of the problem in assessing the potential connection between brain tumors and cell phone use is the relatively short period of time that the devices have been heavily in use in a large population and the long latency period for many tumors.

A National Cancer Institute study published in 2001, for example, did not support the hypothesis that the use of cell phones caused brain tumors, but the researchers noted that a limitation of their work was that they did not assess risks after a potential induction period of more than several years or among people with very high levels of daily or cumulative use (N Engl J Med. 2001;344:79-86).

A 2009 review from researchers at the Karolinska Institutet in Stockholm, Sweden, reported that studies published to date do not demonstrate an increased risk after approximately 10 years of use for any brain tumor or other head tumor (Epidemiology. 2009;20:639-652). Thus far, data do not suggest a causal association between cell phone use and fast-growing tumors, but they note that for slow-growing tumors, such as meningioma and acoustic neuroma, "the absence of association reported thus far is less conclusive because the observation period has been too short."

Another recent review, the third in a series of updates to an original report issued by the Royal Society of Canada, concluded that although there is no clear evidence of adverse health effects associated with radiofrequency fields during the period from 2004 to 2007, continued research is recommended to address specific areas of concern, including the use of cell phones by children (J Toxicol Environ Health B Crit Rev. 2009;12:250-288).

The Interphone studies to date have largely reported negative results, finding no association between tumors and cell phone use. One study did not find a link between an increased risk for malignant or benign parotid gland tumors and exposure to radiofrequency electromagnetic fields, but the authors concluded that cell phones "have not been used long enough to exclude their possible carcinogenic effect after long-term use, and more epidemiologic studies including long-term users are clearly warranted" (Am J Epidemiol. 2006;164:637-643).

However, the results of an Israeli Interphone study suggest a positive association between cell phone use and the development of parotid gland tumors (Am J Epidemiol. 2008;167:457-467). The authors noted that this was a single study, and therefore did not provide enough evidence to assume causality. They recommend additional investigations of this association, with longer latency periods and large numbers of heavy users, to confirm the findings. "Until more evidence becomes available, we believe that the precautionary approach currently adopted by most scientific committees and applied by many governments should continue to be used," they wrote.

Some of the strongest evidence supporting a link between brain tumors and cell phone use comes from a series of Swedish studies, led by Dr. Hardell. Overall, the reserachers found that risk increased with the number of cumulative hours of use, higher radiated power, and length of cell phone use. They also reported that younger users had a higher risk. In fact, the highest risk was among people who were younger than 20 years at the time of first use (Int J Oncol. 2006;28:509-518; Int Arch Occup Environ Health. 2006;79:630-639; Arch Environ Health. 2004;59:132-137; Pathophysiology. 2009;16:113-122).

A meta-analysis that incorporated 11 long-term epidemiologic studies in this field also reported a link between cell phone use and brain tumors. Using a cell phone for 10 years or longer was positively associated with the development of an ipsilateral brain tumor; in fact, it doubled the risk (Surg Neurol. 2009;72:205-214).

Melange of Reactions

As in the literature, there is no consensus among physicians and scientists about the severity of risk, or even if it exists. On its Web site, the National Cancer Institute notes that although a consistent link has not been demonstrated between cell phone use and cancer, "scientists feel that additional research is needed before firm conclusions can be drawn." Likewise, the American Cancer Society points out that although the weight of the evidence has shown no association between cell phone use and brain cancer, information on the potential health effects of very long-term use, or use in children, is not available.

Sam Milham, Jr. MD, MPH, former chronic disease epidemiologist at the Washington State Department of Health and clinical associate professor at the University of Washington School of Public Health in Seattle, has published several critiques on cell phones and health risks. "I personally think there is a real risk, and have felt this way even before the studies were published, based on animal work," he told Medscape Oncology.

Dr. Milham contends that all of the negative studies have been seriously flawed. "The fact that same-sided tumors with long latency are showing increased risks is bad news, since brain tumors have very long latencies," he said. "The same-sided risks are very important since dose is important. The most worrisome fact is the number of people who are being exposed."

Putting a cell phone against your head is like putting one side of your head against a microwave oven," he added.

Last year, Ronald B. Herberman, MD, director of the University of Pittsburgh Cancer Institute and UPMC Cancer Centers in Pennsylvania, sent a memo to faculty and staff advising them to limit cell phone use based on his interpretation of recent research. In 2008, he testified before a Congressional Subcommittee on the subject of tumors and cell phones, and urged more independent and definitive research.

However, many experts are not convinced that there is a link. Currently, there is no evidence that cell phones cause brain cancer, said John Moulder, PhD, professor and director of radiation biology at the Medical College of Wisconsin in Milwaukee.

"The published data have rather consistently shown the absence of evidence for a human health hazard," he told Medscape Oncology. "Conclusive cancer epidemiology requires long follow-up time and accurate exposure assessment. The exposure assessment in this field has been very weak, as it depends on peoples' memories of how they were using mobile phones 10 or more years ago."

He emphasized that the studies based on what side of the head people used their phones are particularly weak, since most people use them on both sides, at least some of the time.

"Until we can find a way to measure actual exposure over long periods of time, the epidemiology will never be conclusive," he added.

Dr. Moulder pointed out a number of flaws in the new report. "The authors seem to have combed the literature for reports that support their concerns, and have ignored everything that would contradict their views," he said. "A scientific risk assessment needs to looks at all the evidence."

Although the report states that cell phone radiation has been shown to cause the blood–brain barrier to leak, Dr. Moulder noted that only 1 group has found that effect. "Other groups have been unable to replicate the effect."

Part of the problem with this research is that it is nearly impossible to prove that something doesn't cause cancer. "The closest you can come is to repeatedly try to show that it does and repeatedly fail," he said.

The Road Ahead

On the heels of the release of the new cell phone report, a Senate hearing on the health effects of cell phone use was held in September, and chaired by Sen. Tom Harkin (D-Iowa). The take-away message from expert testimony was that more and better research is needed to determine if there is a risk to human health. And nearly all of the researchers and scientists who spoke at the hearing advocated a precautionary approach in the meantime.

"We just don't know what the answer is," said Sen. Arlen Specter (D-Pennsylvania) during the hearing. "Precautions are not a bad idea. They may not be a good idea, but they are not a bad idea. And the issue of children is something we should look at a little more closely."

Several countries, including Israel, France, and Finland, and the United Kingdom have decided not to wait for additional data; instead, they have issued warnings about the use of cell phones and advise taking precautionary measures, especially for children. New legislation in France, for example, will ban advertising of cell phones that is directed to children younger than 12 years of age and the sale of cell phones designed for children younger than 6 years. In addition, France will introduce new limits for radiation from the phones and require cell phones to be sold with earphones.

Realistically, it is going to be difficult to change behaviors now that cell phones are so entrenched in daily use, explained Mr. Morgan. "In some parts of the world, it is nearly impossible to get a land-line telephone, so cell phones are the only option."

Cell phones can be made safer, and the technology to do so exists right now. For example, said Mr. Morgan, "you can get a 10,000-fold reduction in exposure simply by keeping the phone 6 inches away from the head."

There are also steps that can be taken right now to make cell phones safer to use, he said. These include using a wired headset (not a wireless headset such as a Bluetooth), using speaker-phone mode, or sending text messages; keeping the phone away from the body when not in use; avoiding use in a moving car, train, or bus, or in rural areas at some distance from a cell tower, because any of these uses will increase the power of the cell phone's radiation; and keeping the cell phone turned off until you need to use it.

The authors also recommend using a corded land-line phone whenever possible, instead of a wireless phone, and to avoid cell phones when inside buildings, particularly with steel structures. Since children face a greater health risk, they should not be allowed to sleep with a cell phone under their pillows or at the bedside, said Mr. Morgan. Ideally, those younger than 18 years should not use a cell phone at all, except for emergencies.

Read more...

PSA Test Is Imperfect Tool: What to Do?

From Medscape Medical News
Nick Mulcahy

Authors and Disclosures

October 1, 2009 — The controversies surrounding population-based screening for prostate cancer — and the problems that plague the use of the prostate-specific antigen (PSA) test — will not go away anytime soon, suggest the authors of a new essay published online September 24 in the British Medical Journal.

There are a host of unanswered questions about PSA screening, including whether or not the test reduces mortality over the long term, assert the essayists.

New data from ongoing trials will provide some answers in the next 5 years or so, lead essayist Jennifer Stark, ScD, an epidemiologist from the Harvard School of Public Health in Boston, Massachusetts, told Medscape Oncology.

However, even with more data on the benefits and risks of the PSA test, it is an imperfect tool for screening men for prostate cancer, Dr. Stark and colleagues say.


"PSA screening cannot differentiate between indolent and lethal prostate cancer," they write.

The test sends many men down a path of diagnostic biopsies and treatment with no certainty of mortality benefit but with much anxiety and overtreatment, she said.

In the United States, the PSA test has triggered the mass overtreatment of men. An estimated 1 million men have been overtreated for prostate cancer since the advent of the widespread screening in the mid-1980s, as recently reported by Medscape Oncology.

What to Do?
Change is clearly in order, suggested a spokesperson for the American Urological Association (AUA). "A complete cultural overhaul is needed to change the perception that all prostate cancer needs to be treated," J. Brantley Thrasher, MD, from the University of Kansas in Lawrence, told Medscape Oncology. The change in perception needs to include clinicians and patients, said Dr. Thrasher.

The change will require physician "re-education" and the consideration of active surveillance as an alternative to treatment, he said.

However, the AUA remains in favor of PSA screening, unlike many other organizations that do not recommend population-based screening because of insufficient data on its benefits and harms. They include the European Urological Association, the US Preventive Services Task Force, Cancer Council Australia, the National Health Committee (New Zealand), the Japanese Urological Association, and the Swedish Board of Health and Welfare, note Dr. Stark and her colleagues.

Recently, at their annual meeting, the AUA issued a revision of their prostate cancer screening guidelines and dropped the age at which men should start to consider baseline PSA testing to 40 years, as reported by Medscape Urology.

"The AUA believes that, when offered and interpreted appropriately,the PSA test may provide essential information for the diagnosis, pretreatment staging or risk assessment, and post-treatment monitoring of prostate cancer," the AUA stated.

At the time, Otis Brawley, MD, chief medical officer of the American Cancer Society, told WebMD that the call for a baseline PSA at age 40 will likely lead to more screening and more overtreatment of men who will not benefit.

Patients Must Be Well Informed About Initial PSA — But How?

In their essay, Dr. Stark and colleagues agree that the PSA test needs to be offered appropriately, and describe that change as "urgently needed." Echoing the AUA, they recommend that men be well informed about the test before having the blood work done.

"You wouldn't just decide on the spot to do a mammogram," said Dr. Stark, explaining that such quick decisions are common with PSA testing.

"Somehow, we have to approach screening for prostate cancer with the same prudence we would have in screening for breast cancer or colon cancer," she added.

However, as recently reported by Medscape Oncology, the primary care setting, where most PSA testing is done initially, is currently ill-suited for discussing the complexities of prostate cancer screening.

"Today's practice environment presents few incentives or support tools for those clinicians and patients who prefer a discussion rather than simply marking a checkbox for PSA on a laboratory requisition form," Steven H. Woolf, MD, MPH, and Alex Krist, MD, MPH, from Virginia Commonwealth University in Richmond, write in an editorial published in the September 28 issue of Archives of Internal Medicine (2009;169:1557-1559).

That editorial accompanied a paper detailing results from a survey, which showed that nearly one third of men receiving a PSA test did not have any discussion with their doctor about the test (Arch Intern Med. 2009;169:1611-1618).

Interpretation of PSA Test

Another point highlighted by Dr. Thrasher in the interview with Medscape Oncology was that PSA test results should not be considered on their own, but need to be interpreted along with other information.

"PSA does not work well by itself in predicting prostate cancer," Dr. Thrasher said.

The interpretation of PSA tests by a urologist should always be done in conjunction with other factors that contribute to prostate cancer risk, such as overall health, family history, age, comorbidities, the rate of change in PSA value over time (PSA velocity), and physical examination, Dr. Thrasher explained, referring to the AUA's Prostate-Specific Antigen Best Practice Statement.

"I don't want people to walk away from PSA and say it's useless," he remarked. "We believe we are still saving lives with the test."

More Unanswered Questions

New data from ongoing trials will provide answers to some of the questions that remain about PSA testing, including the crucial question of whether it reduces mortality, Dr. Stark told Medscape Oncology.

Two major trials are evaluating the effectiveness of PSA screening — the European Randomized Study of Screening for Prostate Cancer (ERSPC) and, in the United States, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO).

Recent published data from these trials involved a median follow-up of 7 years in the United States and 9 years in Europe (N Engl J Med. 2009;360:1310-1319 and 1320-1328). Those results showed no affect on mortality from prostate cancer in the American trial, and a small reduction in mortality in the European trial, as reported by Medscape Oncology.

Lead time, or the interval of time by which screening advances a diagnosis, is necessary to reduce morbidity and mortality associated with disease, write the Dr. Stark and her coauthors. It has been estimated that mean lead times for PSA testing were 11 to 13 years among men aged 50 to 69 years, which is "much longer" than for other cancer screening, they write. This time frame explains Dr. Stark's contention that, in another 5 years, ERSPC and PLCO will provide answers to some currently unanswered questions about PSA screening.

With continued follow-up in these major trials, there should be answers to questions about the predictive value of a negative PSA result (what percentage of men go on to have prostate cancer despite the negative result?), and solid information on the percentage of men who are overdiagnosed, Dr. Stark said. The screening trials will also be able to firmly determine how many men need to be treated to avert 1 death; the ERSPC estimate is currently 48, she added.

With regard to the question of what percentage of men are overtreated, although the trials will be helpful, the answer might require more extended follow-up, said Dr. Stark.

"Because of the long life expectancy of many men diagnosed with prostate cancer, combined with the long lead time for PSA screening, it is going to take considerably longer to determine who ultimately benefits from treatment of a screen-detected cancer and how this benefit compares with the side effects and mortality associated with treatment," she said.

The essay authors have disclosed no relevant financial relationships.

BMJ. 2009;339:b3601. Abstract


Read more...

Tumors of the Stomach & Small Intestine

Common gastric and small intestine malignancies include adenocarcinoma, lymphoma, metastatic carcinoma, gastrintestinal stromal tumors, and carcinoid. These must be differentiated from benign ulcerative lesions and polyps by endoscopic or surgical biopsy
Symptoms and signs include dyspepsia, weight loss, obstructive symptoms, and evidence of intestinal blood loss or iron deficiency anemia.
Diagnosis of early stage gastric cancer requires a high index of suspicion for patients who are at increased risk, for examplein patients aged over 40-45 years, history, prior history of pernicious anemia, celiac sprue, immunodeficy or gastric polyps. Diagnosis requires refferal for endoscopy and/or barium radiologic exams.
Diagnosis of small bowel tumors often requires a barium enteroclysis examination performed by an experienced radiologist or endoscopy using small bowel enteroscopes





The stomach and less frequently the small intestine give rise to a variety of benign and malignant tumors. In 5000 endoscopic examinations of the stomach conducted over a 7 years perioed at University of Chicago, aproximately 119 gastric malignancy (2,4%) and 125 benign gastric polyps (2,5%)were diagnosed. The most gastric malignancies is adenocarcinoma, followed by primary gastric lymphoma, metastatic carcinoma, and less frequently leiomyosarcoma, carcinoid and kaposi's Sarcoma.
Gastric cancer is particularly common in Japan, China, Korea, Taiwan, Eastern Europe and countries of the former Soviet union , Costa Rica, and South America.
Read more...

CARCINOMA PROSTATE

The risk of carcinoma of the prostate increases with age, being increasingly detectable from 50-80 years. Though the cause is unknown, several factors influence the risk. Geographical (Sweden and USA), racial (blacks) and occupational (rubber workers) factors and altered oestrogen and androgen levels are some of the risk factors.



Adenocarcinoma arising from the glandular acini is the most common. Sarcomas, and squamous cell, transitional cell and small cell carcinomas are other tumours. Apart from these, metastases to prostate are seen from the bladder, lung, colon and lymphomas. Grossly, multifocal lesions and invasion of the prostatic capsule are the characteristic features of this disease. It most commonly metastasises to bone, with dense osteoblastic or osteolytic lesions, and less frequently to the liver and lung with paraneoplastic syndromes.

Early prostatic carcinoma is usually asymptomatic and can be detected by routine rectal examination. Induration or non tender nodularity are the frequent findings. The presence of symptoms indicates advanced disease. Urinary symptoms like sudden onset of urinary tract obstruction, poor urine flow, urgency and terminal haematuria, back pain or paraplegia may be due to extradural secondaries. Acute and chronic prostatitis, nodular hyperplasia and benign adenomas have to be clinically differentiated from prostatic carcinoma.

The histological diagnosis is established by transperitoneal needle biopsy or by transrectal fine-needle aspiration cytology (FNAC). Routine investigations like urine analysis, complete blood picture, renal and liver profile, serum alkaline phosphatase, serum calcium and phosphorus levels, chest X-ray, and X-ray of bony secondary sites are carried out (Fig. 14.6). Ultrasonography, CT scan, isotope bone scan and lymphangiogram are optional. Estimation of acid phosphatase levels in serum is not considered very specific for carcinoma prostate. Prostate-specific antigen (PSA) is more sensitive and useful. Carcinoembryonic antigen is increased in a few cases.

Routine and careful examination of the prostate after 50 years of age is essential for prevention and early diagnosis of carcinoma prostate. Surgery, radiotherapy and hormonal manipulation are modalities of treatment.In cases diagnosed incidentally at histology during transurethral resection of suspected benign prostatic hyperplasia, random multiple needle biopsies are carried out. If no further foci are detected, patients are kept on follow-up without any further treatment.A tumour which is palpable but is confined to the prostate (single nodule of less than 2 cm) is managed with radical prostatectomy. However, few patients with carcinoma are diagnosed early and are fit for surgical treatment. Tumours with multifocal lesions or those localised to the periprostatic area are managed by radical prostatectomy or radiotherapy. This group of patients needs pelvic lymphadenectomy for pathological staging before prostatectomy, as radical treatment depends on the stage of the disease. The increased incidence of impotency, lymphoedema, pulmonary embolism are limiting factors of radical surgery.

External radiotherapy is widely employed in the management of carcinoma prostate, either alone or as adjuvant to radical prostatectomy. Interstitial implant irradiation using I-125, Ir-192, Au-198, P-32 isotopes is also used. Neither hormonal therapy nor chemotherapy has improved survival in early stages of carcinoma prostate.In advanced stages transurethral resection of the prostate is done to relieve the bladder outlet obstruction as a purely palliative measure. Orchidectomy is also effective. Radiotherapy is useful in isolated painful bony secondaries, spinal cord compression, pelvic pain syndromes and haematuria. Endocrine therapy is the mainstay of treatment of symptomatic prostatic malignancy. Orchidectomy, luteinising hormone-releasing hormone (LH-RH) agonists and oestrogens result in dramatic improvement. Long-acting oestrogen chlorotriamisene (TACE), progestins, flutamide (anti-androgen), aminoglutethamide and diethylstilbesterol diphosphate can be used. Chemotherapy is given for hormone-resistant cases. Multi-drug chemotherapy has not shown superior results over single-agent therapy. Adriamycin, 5-fluorouracil, methotrexate, cyclophosphamide, cisplatin and DTIC are used.

Survival is directly related to stage: stages I and II-70%, stage III-56% and stage IV-25% at 5 years. Well differentiated carcinomas have better prognosis. Grades I, II, III and IV carry 5-year survival of 60%, 35%, 15% and 5%, respectively. Involvement of seminal vesicles is associated with poor prognosis.

Read more...

Five important guidelines of Make Love

Sexual activity before intercourse which called foreplay by most expert says not true instead mean nothing but "sexual intercourse warming". The word foreplay give a huge stress for men to have erective penis and tend to bring our thinking that sex is only intercourse. Demikian pendapat yang disampaikan Joel D. Block, PhD dalam bukunya yang berjudul “Secrets of Better Sex”.



According to Joel, the right term for it is “Loveplay”. Commonly the period called ‘foreplay’ regarde as a must step for a men to his partner ini dianggap sebagai langkah yang harus dilakukan oleh seorang pria terhadap pasangan wanitanya supaya siap berhubungan seks karena pria dianggap selalu siap. Kenyataannya, pria, terutama yang sudah lanjut usia sangat membutuhkan dan menginginkan loveplay sebelum atau selama hubungan seks. Sebagai sebuah persiapan menuju hubungan badan yang sesungguhnya, foreplay akan lebih mampu meningkatkan gairah seksual bila dijalankan dengan benar. Berikut ini lima petunjuk untuk Foreplay menurut Joel. D.Block:1. Ingatlah bahwa seks dimulai di otak. Start thinking about sexual intercourse time and tell your thinking briefly, it is better by drawing a picture to your partner if you can. It can achieve by using another symbol, like send her a rose to her office. Give attention to romantic things. Siapkan suasana yang sedikit romantis. Pastikan ruangan cukup hangat, pencahayaan yang tepat, bau ruangan yang harum, pakaian dalam yang merangsang, dan sebagainya.3. Perlahan-lahan. Mulailah dengan mencium (jangan langsung pada organ seks).4. Berikan orgasme. Banyak wanita tidak mengalami orgasme saat berhubunga seksual. Sebagian wanita yang mengalami orgasme beberapa kali jauh lebih mungkin mendapatkan orgasme yang kedua atau ketiga selama berhubungan seksual jika mereka pernah mengalaminya.5. Perhatikan zona erotik lain. Ada banyak zona erotik, misalnya putting, skrotum (pada pria) atau tempat-tempat lain seperti telinga, leher, dan sebagainya.

Read more...

Early detection on cancer cell

Cancer recurence because of cancer cell spreading after treatment series must avoid reminding of cancer death number still high. For that purposes, early and acurate detection on cancer cell spreading needed.
”With early detection, terapeutic respons of cancer can be determined,” says Head of Radiology Departement Gading Pluit Hospital dr Tjondro Setiawan, on official announcement of PET-CT Scan dan Cyclotron center, Monday (17/11), at Gading Pluit Hospital, Jakarta. The official announcement was done by Minister of Research and Technology Kusmayanto Kadiman and General Director Management of Medical Services of Health Departement Farid Husein.



Cell alteration detection
There are so many tools was developed in early detection on cancer, neurological disturbance, and cardiovascular so far, such as computed tomography (CT-Scan), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET). ”And now, we have PET-Scan and Cyclotron which become the first facility in Indonesia,” says Tjondro.
PET-CT Scan is 3 colour dimension scan to detect alteration or cell activity inside the body using radiopharmacy. With nuclear technology, PET-CT Scan can give exact image of abnomally growth body cell location.

Taken from: Kompas daily, Tuesday November 18, 2008

Read more...

What's the impact of advance medical examination?

Today, medicine science has improve rapidly. More medical examination items have invited, and some of them is invasif methode of examination. Let's say cardiac catheterisation, colonoscopy, bronchoscopy and others. Some of them are not invasive methode but still, give big impact to whom examined using the methode.

Some patient, prever not go to medical facilities because they imagine how pain, tired and scarry walking trough a medical examination, especially the invasive one. This implications have to think by physician and health care provider in order to give maximum service to their patients. But still, we found medical provider like doctor ordered some additional examination without considering patient psychologic condition.

Other examination give impact to patient after long time they done the examination. Examination using a radioisotop for example. It can give radiation to patient body, and can affect body organ and cellular function. While other examination like rectal or vaginal examination can affect to patient comfort. And should perform carefully to make sure patient safety and comfort

Read more...